These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10516341)

  • 1. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy.
    Remuzzi A; Fassi A; Bertani T; Perico N; Remuzzi G
    Am J Kidney Dis; 1999 Oct; 34(4):626-32. PubMed ID: 10516341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.
    Windt WA; van Dokkum RP; Kluppel CA; Jeronimus-Stratingh CM; Hut F; de Zeeuw D; Henning RH
    Eur J Pharmacol; 2008 Feb; 580(1-2):231-40. PubMed ID: 18036585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
    Zoja C; Corna D; Bruzzi I; Foglieni C; Bertani T; Remuzzi G; Benigni A
    Exp Nephrol; 1996; 4(4):213-21. PubMed ID: 8983642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats.
    Remuzzi A; Malanchini B; Battaglia C; Bertani T; Remuzzi G
    Exp Nephrol; 1996; 4(1):19-25. PubMed ID: 8788596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
    Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
    Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.
    Haas M; de Boer E; de Jong PE; Moolenaar F; Meijer DK; de Zeeuw D
    Clin Sci (Lond); 2003 Jul; 105(1):51-7. PubMed ID: 12636872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.
    Remuzzi A; Gagliardini E; Sangalli F; Bonomelli M; Piccinelli M; Benigni A; Remuzzi G
    Kidney Int; 2006 Apr; 69(7):1124-30. PubMed ID: 16395266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
    Remuzzi A; Gagliardini E; Donadoni C; Fassi A; Sangalli F; Lepre MS; Remuzzi G; Benigni A
    Kidney Int; 2002 Sep; 62(3):885-94. PubMed ID: 12164870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis.
    Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G
    Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G
    Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage.
    Kramer AB; Laverman GD; van Goor H; Navis G
    J Pathol; 2003 Sep; 201(1):160-7. PubMed ID: 12950029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.
    Bos H; Laverman GD; Henning RH; Tiebosch AT; de Jong PE; de Zeeuw D; Navis G
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):106-12. PubMed ID: 12806593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
    Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
    J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
    Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
    Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition.
    Macconi D; Sangalli F; Bonomelli M; Conti S; Condorelli L; Gagliardini E; Remuzzi G; Remuzzi A
    Am J Pathol; 2009 Mar; 174(3):797-807. PubMed ID: 19164508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis.
    Kramer AB; Ricardo SD; Kelly DJ; Waanders F; van Goor H; Navis G
    J Pathol; 2005 Dec; 207(4):483-92. PubMed ID: 16211543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
    Waanders F; van Goor H; Navis G
    Kidney Blood Press Res; 2008; 31(5):350-9. PubMed ID: 19018148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation.
    Smit-van Oosten A; Navis G; Stegeman CA; Joles JA; Klok PA; Kuipers F; Tiebosch AT; van Goor H
    J Pathol; 2001 May; 194(1):122-9. PubMed ID: 11329151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.